Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Monoclonal Antibodies (Bamlanivimab and Casirivimab + Imdevimab) for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459 is registered in ClinicalTrials.gov with Sohail Rao as lead sponsor.

NCT NCT04840459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04840459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Monoclonal Antibodies (Bamlanivimab and Casirivimab + Imdevimab) for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
Lead sponsor
Sohail Rao
Phase
Phase 2
Overall status
Unknown status
Start date
November 20, 2020
Completion date
January 31, 2023
Enrollment
1,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19